bempegaldesleukin
Recombinant proteinexperimental
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics. — Wikipedia
Clinical trial activity
12 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Mar 15, 2018 (NCT03435640)
Timeline
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 3
- Colorectal Neoplasms · Phase 1/Phase 2
- COVID-19 · Phase 1
- Healthy Volunteers · Phase 1
- Melanoma · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Sarcoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2/Phase 3
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBempegaldesleukin ↗
- ChEMBLCHEMBL4298058 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07156643 | Phase 2 | Oct 1, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Nanjing Medical University |
| NCT06921941 | Phase 1 | Apr 8, 2025 | Atea Pharmaceuticals, Inc. |
| NCT04969861 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2021 | Merck, Nektar Therapeutics, SFJ Pharmaceuticals, Inc. |
| NCT04646044 | Phase 1 | Nov 13, 2020 | Nektar Therapeutics |
| NCT04540705 | Phase 1/Phase 2 (Phase 2) | Sep 3, 2020 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT04410445 | Phase 3 | Aug 31, 2020 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT04955262 | Phase 1 | Aug 31, 2019 | ImaginAb, Inc., Nektar Therapeutics |
| NCT04052204 | Phase 2 | Aug 29, 2019 | Astellas, Merck Serono, Nektar Therapeutics, Pfizer |
| NCT03785925 | Phase 2 | Apr 29, 2019 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT03729245 | Phase 3 | Dec 28, 2018 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT03548467 | Phase 1/Phase 2 (Phase 2) | Apr 4, 2018 | Sponsor GmbH, Vaccibody AS |
| NCT03435640 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2018 | Nektar Therapeutics |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nektar Therapeutics | For profit | 9 | 7 | 3 | 2018 |
| Bristol-Myers Squibb | For profit | 4 | 1 | 2 | 2018 |
| Astellas | For profit | 1 | 0 | 1 | 2019 |
| Atea Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2025 |
| ImaginAb, Inc. | For profit | 1 | 0 | 1 | 2019 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 0 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| Merck Serono | For profit | 1 | 0 | 1 | 2019 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Pfizer | For profit | 1 | 1 | 1 | 2019 |
| SFJ Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Vaccibody AS | For profit | 1 | 1 | 1 | 2018 |
13 organizations
Page 1 / 1